by Amministratore Nethics | Jan 20, 2025 | Relatori
Dr. Hunter Land, PhD, MS, has a deep knowledge of cannabinoid science spanning over two decades of research and development across 25 therapeutic areas. He has dedicated 12 years to advancing cannabinoid research, notably overseeing large scale R&D projects that...
by support | Oct 28, 2024 | Relatori
Brendan Hughes (British) has been working at EMCDDA/EUDA since 2001 in the field of national drug legislation, after gaining a Masters degree in International Criminal Law (LLM) specialising in narcotics law. He has written various comparative overviews and analyses...
by support | Oct 21, 2024 | Relatori
Mauro Maccarrone is a Professor of Biochemistry at the University of L’Aquila, Italy, and Head of the Lipid Neurochemistry Unit at the European Center for Brain Research in Rome. He has published extensively, with 24,702 citations and an h-index of 83 (Scopus), and...
by support | Oct 18, 2024 | Relatori
Colin Stott is the COO of Phytanix Bio. He is the former Research & Operations Director (from 2001 to 2017) and International Scientific Affairs Director of GW Pharmaceuticals (from 2017 to 2019) and was closely involved in the development and approval of the...
by support | Oct 18, 2024 | Relatori
Professor Guy founded GW Pharmaceuticals plc in 1998, a world leader in cannabinoid therapeutics, and was Chairman until its sale in May 2021. Geoffrey has been the physician in charge of over 300 clinical studies, author on over 80 scientific papers and has written 3...
by support | Oct 18, 2024 | Relatori
Andrea holds a Ph.D. in Pharmacology with over 15 years of experience. He was appointed Adjunct Professor at the University of Bern’s Medical Faculty and completed a Master of Advanced Studies in Translational Medicine and Biomedical Entrepreneurship. After his...
Recent Comments